REFLAB ApS: Financial statements 2014
CVR: 15322586
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
REFLAB ApS (CVR 15322586) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK 4,638,963 and a net result of DKK 1,080,544 compared with DKK 98,128 the year before. That is an increase of 26.8% compared with the year before. Equity in the 2014 report amounted to DKK 3,861,471. The solvency ratio was 76.2%.
- Gross Profit
- DKK 4,638,963
- Profit/Loss
- DKK 1,080,544
- Equity
- DKK 3,861,471
- Total Assets
- DKK 5,069,805
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | 4.6 mio. | 1.1 mio. | 3.9 mio. | - |
| 2013 | - | 3.7 mio. | 98 t. | 2.8 mio. | - |
| 2012 | - | 2.5 mio. | -65 t. | 2.7 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
REFLAB ApS has published its annual report for 2013. Gross profit came to DKK 3,659,419, and the net result was DKK 98,128.
About REFLAB ApS
REFLAB ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 1991. The company is registered under the industry Traditionelle, komplementære og alternative behandlingsformer. The company was previously named REFERENCELABORATORIET ApS. The management consists of Gert Pynt Andersen and Katrine Baumann Markussen. The company is owned by R-Biopharm AG. The company has 7 employees (2018). In 2025, the company reported a gross profit of DKK 4,582,184 and a net result of DKK -1,792,430 compared with DKK 652,577 the year before. Equity in the 2025 report amounted to DKK -635,048.